Creative Biolabs is a cellular immunotherapy company dedicated to the development of innovative T cell therapies for the treatment of diseases with a high unmet medical need. Benefiting from our expertise in CAR-T cell development, we are able to harness science and technology to create CAR-Tregs products that support the next generation of cell therapy innovation.
Challenges for Conventional CAR-T Cell
CAR-T cell therapy has shown remarkable efficacy in the treatment of liquid tumors such as acute leukemia and non-Hodgkin's lymphoma, and is therefore considered to be one of the most promising cell-based immunotherapies. However, until recently, the use of CAR T cell therapy was limited to small clinical trials, primarily because these therapies caused a variety of worrying, sometimes fatal side effects in some patients. The most common one is the cytokine release syndrome (CRS). In addition, evidence suggests that CAR-T cells are targeted to activate antigens expressed on T cells, which are transformed into inducible Treg cells as tumor metastasis progresses. Therefore, the innovative CAR cell therapy targeting Treg has attracted the attention of researchers and the public.
Advantages of CAR-Treg Cells
Cellular therapies using polyclonal regulatory T cells (Tregs) in transplantation and autoimmune diseases have been performed in both animal models and clinical trials. However, polyclonal Tregs cause adverse reactions, such as systemic immunosuppression, since a large number of cells are of unknown antigen specificity. This can be avoided by utilizing antigen-specific Tregs, that is, by transfecting the viral vector encoding the chimeric antigen receptor (CAR) of a specific antigen into Treg to achieve precise modification. Recognized advantages include:
Fig.1 Schematic representation the structure of CAR-modified regulatory T cells (CAR-Tregs). (Zhang, 2018)
One-stop CAR-Treg Therapy Development
For more detailed information, please feel free to contact us or directly sent us an inquiry.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE